MedTrace Logo

Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A

NCT04874142 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-05-05

No results posted yet for this study

Summary

To evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A

Conditions

  • Dyslipidemias

Interventions

DRUG

YYC506-T

single administration

DRUG

YYC506-A

single administration

DRUG

YYC506-T + YYC506-A

concomotant administration

DRUG

YYC506-A + YYC506-T

concomotant administration

Sponsors & Collaborators

  • Yooyoung Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Kyu Park, PhD · ChungBuk National Unviersity Hospital.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-20
Primary Completion
2020-03-23
Completion
2020-03-23

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04874142 on ClinicalTrials.gov